Answers are grounded in this paper and cite their sources.
The aim of this study was to formulate polymer-based artesunate nanoparticles for malaria treatment. Artesunate was loaded with poly( D,L -lactic- co -glycolic acid) (PLGA) by solvent evaporation from an oil-in-water single emulsion. Nanoparticles were characterized by X-ray diffraction and differential scanning calorimetry analyses. In vivo antimalarial studies at 4 mg/kg were performed on Swiss male albino mice infected with Plasmodium berghei . Hematological and hepatic toxicity assays were performed. In vitro cytotoxicity of free and encapsulated artesunate (Art-PLGA) to cell line RAW 264.7 was determined at concentrations of 7.8–1000 μg/ml. The particle size of the formulated drug was (329.3±21.7) nm and the entrapment efficiency was (38.4±10.1)%. Art-PLGA nanoparticles showed higher parasite suppression (62.6%) compared to free artesunate (58.2%, P <0.05). Platelet counts were significantly higher in controls (305 000.00±148 492.40) than in mice treated with free artesunate (139 500.00±20 506.10) or Art-PLGA (163 500.00±3535.53) ( P <0.05). There was no sign of hepatic toxicity following use of the tested drugs. The half maximal inhibitory concentration (IC 50 ) of Art-PLGA (468.0 μg/ml) was significantly higher ( P <0.05) than that of free artesunate (7.3 μg/ml) in the in vitro cytotoxicity assay. A simple treatment of PLGA-entrapped artesunate nanoparticles with dual advantages of low toxicity and better antiplasmodial efficacy has been developed.
No takes yet. Share an insight, caveat, or question.
Dauda et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: